Study S000774

Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.

ClinicalTrials.gov record

Registration

Registration: NCT04781998
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2021-07-01
Primary completion: 2022-07-21
Lead sponsor: Anders Fink-Jensen, MD, DMSci
Conditions: Mental Disorder; Metabolic Disturbance; Feasibility; Overweight and Obesity; Liraglutide
Interventions: DRUG:liraglutide 3 mg (Saxenda®) once-daily
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The primary endpoint is the number of "completers" [26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.